08Jul/13

Breast cancer drug everolimus fails to get NICE approval – OnMedica


The Guardian

Breast cancer drug everolimus fails to get NICE approval
OnMedica
The breast cancer drug everolimus (also called Afinitor) is not cost effective for the NHS. This is the recommendation from the National Institute for Health and Care Excellence (NICE) which today refused to give the green-light to everolimus
Novartis breast cancer drug Afinitor not cost effective for NHS, says draft The Pharma Letter
Breast cancer drug rulingITV News
Novartis Cancer Drug Fails to Win U.K. Cost Agency’s NodBloomberg
The Guardian –Guernsey Press and Star (subscription)
all 27 news articles »